

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 057 480 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
06.12.2000 Bulletin 2000/49

(51) Int Cl.⁷: **A61K 9/70, A61K 31/40,
A61P 5/32**

(21) Application number: 00304611.7

(22) Date of filing: 30.05.2000

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 01.06.1999 US 137164 P

(71) Applicant: **Pfizer Products Inc.
Groton, Connecticut 06340 (US)**

(72) Inventor: **Da Silva-Jardine, Paul Andrew
Groton, Connecticut 06340 (US)**

(74) Representative:
**Simpson, Alison Elizabeth Fraser et al
Urquhart-Dykes & Lord,
30 Welbeck Street
London W1M 7PG (GB)**

(54) **Transdermal estrogen agonist-antagonist therapy**

(57) This invention provides a method for transdermal delivery of estrogen agonists - antagonists which

are effective for treating or preventing conditions related to estrogen imbalance.

EP 1 057 480 A2

Description

FIELD OF THE INVENTION

5 [0001] This invention relates to transdermal estrogen agonist-antagonist (SERM) therapy for humans in need of such treatment. In particular, this invention relates to a method which involves transdermal delivery of 5-substituted-6-cyclic-5,6,7,8-tetrahydronaphthalene-ol compounds which are estrogen agonists-antagonists effective for treating or preventing conditions related to estrogen imbalance including breast cancer, osteoporosis, obesity, cardiovascular disease, hypercholesterolemia, endometriosis and prostate disease.

10

DESCRIPTION OF RELATED ART

[0002] Transdermal drug delivery systems are known in the art. Some patents in this area are concerned with the transdermal delivery of hormone formulations for various purposes. Examples of such patents are as follows:

15 [0003] U.S. Pat. No. 4,816,258 issued Mar. 28, 1989 to Nederberge et al discloses a drug formulation of ethinyl estradiol and levo-norgestrel for transdermal administration which comprises a matrix containing the steroids and a skin permeation enhancing amount of glycerol monooleate.

[0004] U.S. Pat. No. 5,122,382 issued Jun. 16, 1992 to Gail et al discloses a composition for transdermal administration comprising an estrogen and ST-1435. The formulation delivers certain quantities per day of the steroids and includes a skin permeation enhancer.

20 [0005] U.S. Pat. No. 5,023,084 issued Jun. 11, 1991 and U.S. Pat. No. 4,906,169 issued Mar. 6, 1992, both to Chien et al describe a combination of estrogen and progestin in a contraceptive formulation with a transdermal unit comprising a backing layer containing the hormones and an adhesive layer.

[0006] U.S. Pat. Nos. 4,624,665, issued Nov. 25, 1986; 4,687,481 issued Aug. 18, 1987; 4,834,978 issued May 30, 1989; and, 4,810,499 issued Mar. 7, 1989 and 4,927,687 issued May 22, 1990 describe a transdermal delivery system which is said to prevent dose dumping of the drug to be delivered caused by accidental rupture of a retaining member and ensures effective and prolonged delivery of the drug, particularly contraceptive steroids. Suitable steroids include norethindrone, norgestrel, estradiol, levó-norgestrel and mestranol.

30 [0007] U.S. Pat. No. 5,422,119 describes a method of transdermally administering to a female in need of hormone replacement therapy a series of estrogen and progestin in alternate phases.

[0008] U.S. Pat. No. 5,552,412 describes the estrogen agonist-compounds which are employed in this invention. This patent is incorporated herein by reference.

[0009] WO97/43989 describes hydrogel compositions which are useful for transdermal delivery of drugs.

35 [0010] EP 0 328 806 describes a transdermal therapeutic system without membrane; its matrix consists of a polyacrylate adhesive, a solvent, a penetration enhancer, and estrogen, its derivatives and combinations thereof.

[0011] WO 87/07 138 describes an estradiol patch having a backing layer, an active substance-containing matrix, and a pressure-sensitive adhesive covered with a removable protective layer. Matrix and pressure-sensitive adhesive are manufactured in operations involving considerable technological expenditure, i.e., by homogenizing, degassing, coating, drying, and separating. According to an embodiment the backing layer has to be coated with a pressure-sensitive adhesive, requiring an additional operation. The individual parts are joined in a separate step. For this reason, the production of this patch is very expensive and complicated.

40 [0012] EP 0 186 019 describes active substance patches wherein water-swellaable polymers are added to a rubber/adhesive-resin-mass and from which estradiol can be released. It turned out, however, that the estradiol release from these active substance patches is absolutely insufficient and fails to meet the therapeutic requirements.

45 [0013] DE-OS 20 06 969 describes a patch or a pressure-sensitive adhesive dressing exhibiting system action, wherein contraceptive substances are incorporated in the adhesive component or in the adhesive film. The adhesive film may be an acrylate.


SUMMARY OF THE INVENTION

50


[0014] This invention provides a method of treating a human in need of estrogen agonist-antagonist therapy comprising administering to said human an effective amount of said estrogen agonist-antagonist by transdermal means.

[0015] This invention further provides a method of treating a human in need of estrogen agonist-antagonist therapy comprising administering by transdermal means to said human an estrogen agonist selected from a compound of the formula

55



wherein G is



and

R is H, OH, F or Cl

[0016] This invention further provides a method of treating a human in need of estrogen agonist-antagonist therapy wherein said transdermal means is a transdermal patch or a hydrogel composition.

[0017] This invention further provides a transdermal patch which provides administration of said estrogen agonist-antagonist to said human over a period of three to fourteen days in substantially equal amounts of 10-500 µg per day.

[0018] This invention further provides a transdermal patch comprising a matrix and a pharmaceutically effective amount of (-)-cis-5-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof.

[0019] In a preferred form of the present invention a patch of an adhesive matrix type or a drug reservoir type is prepared containing sufficient estrogen agonist-antagonist to provide a transdermal delivery rate of about 10-500 µg per day.

[0020] The selection of estrogen agonists-antagonists most suited for transdermal delivery may be determined by conventional tests used in the art to determine skin permeability. The most common is the In Vitro Skin Protection Chamber using hairless mouse skin or human cadaver skin. The literature contains much information on these tests and the following references are typical:

- a) Kao J, Hall J. Skin Absorption and Cutaneous First Pass Metabolism of Topical Steroids: In Vitro Studies with Mouse Skin in Organ Culture. J Pharmacol Exp Ther 241(2), pp 482-487, 1987;
- b) Tojo K, Lee C. A Method for Predicting Steady-state Rate of Skin Penetration In Vivo. J Invest Derm 92(1), pp 105-108, 1989;
- c) Liu P, Higuchi WI, Song W, Kurihara-Bergstrom T, Good WR. Quantitative Evaluation of Ethanol Effects on Diffusion and Metabolism of β-Estradiol in Hairless Mouse Skin. Pharm. Res 8(7), pp 865-872, 1991; and
- d) Roy S, Gutierrez M, Chiang C. Permeation of Norethindrone, Norethindrone Acetate and Norethindrone Diacetate Through Cadaver Skin. Pharm Res Suppl 6, p 1168, 1989.

[0021] In selecting suitable estrogen agonists-antagonists, skin permeation and hence transdermal delivery rates are important, but also, the stability of the estrogen agonists in the formulation can be a factor. Stability can be assessed or measured in two basic ways: visual inspection and in vitro dissolution.

[0022] Visual inspection is generally conducted on both a macroscopic and a microscopic level of crystal formation. As for in vitro dissolution, there are tests for in vitro release rates which are standard in the art. Generally when these criteria are met, the transdermal delivery rates required are readily achieved.

[0023] There are a number of transdermal patches available commercially which may be used in the present method. Two such patches are described here for purposes of exemplification only, but others may be employed.

[0024] In one known system, a matrix of a solid adhesive of acrylic copolymer base containing hormones in dissolved form is employed. The system involves the use of a flexible backing foil which may comprise for example polyethylene terephthalate. A release liner forms another layer (in contact with the adhesive). A swellable polysaccharide, galactomannan is added to the adhesive matrix to improve the adhesion between the surface of the patch and hydrated skin, over the whole application, and to reduce irritation phenomena caused by occlusion effects. Preferably, a three layer laminate is produced of the backing foil, drug matrix and release liner. Currently, a commercial product of this nature

is sold under the trade mark SYSTEM TTS.

[0025] Another commercial product is that available under the trade mark ESTRADERM. ESTRADERM™ is an estradiol transdermal system designed to release estradiol through a rate-limiting membrane continuously upon application to intact skin. The ESTRADERM™ system comprises five layers: a backing layer, a drug reservoir, a control membrane, an adhesive layer and a protective layer in that order from outside to inside. The qualitative composition of the ESTRADERM drug reservoir is estradiol, alcohol and hydroxypropyl cellulose.

[0026] For transdermal administration, as has already been stated, any suitable form of patch may be selected. Another which is known to be useful in the administration of hormone formulations is described in detail in U.S. Pat. No. 4,668,232 issued May 26, 1987 to Cordes and Wolff, the disclosure of which is incorporated herein by reference. In this U.S. patent, the system described is a four layer system comprising an impermeable backing or covering layer; a reservoir layer adjacent to the backing or covering layer; an adhesive layer permeable to the hormones and a protective layer which is removed before application of the patch. As described earlier, a three layer system may be used which comprises a backing layer, a drug matrix adhesive layer and a release liner.

[0027] An estrogen agonist-antagonist patch for the present invention may be prepared using an ethanolic gel type of drug reservoir. The weight of hormone, preferably (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol is about 140-7000 µg. The patch may have a surface area of about 18 cm². In appearance it may be ground with the reservoir comprising about 10 cm² of the patch. This generally provides a transdermal delivery rate of about 10-500 µg per day.

DETAILED DESCRIPTION OF THE INVENTION

[0028] In a preferred mode, the present invention relates to an active substance-containing patch for the controlled release of an estrogen agonist amount or pharmaceutically acceptable derivatives alone or combined with other compounds, consisting of a backing layer, an active substance-containing reservoir which is bonded thereto and is produced by using pressure-sensitive adhesive comprising ethylcellulose, esters of non-hydrogenated and/or hydrogenated colophony, and lauric acid.

[0029] Ethylcellulose is a cellulose ether produced by reacting ethyl chloride with alkali cellulose. With respect to the structure, it is generally assumed that a cellulose molecule is a chain of anhydroglucose or cellobiose units bound by oxygen bridges. These long chains of anhydroglucose with oxygen bridges are very stable and have good flexibility. These properties are utilized in the estrogen agonist-containing patch according to the present invention to render the pressure-sensitive adhesive sufficiently cohesive, this is required to remove the patch from the skin without leaving any residue after completed application. The pressure-sensitive adhesive comprises ethylcellulose in a proportion of 5-25% wt., preferably 8-14% wt.

[0030] Examples of esters of colophony include, for example, methyl ester, glycerol ester, pentaerythritol ester, pentaerythritol ester modified with maleic acid, glycerol ester modified with maleic acid, and triethylene glycol ester. The proportion of colophony esters in the estrogen agonist-containing pressure-sensitive adhesive amounts to 50-90% wt., preferably 60-80% wt.

[0031] The pressure-sensitive adhesive may comprise esters of hydrogenated colophony either alone or together with esters of non-hydrogenated colophony.

[0032] Particularly preferred esters of colophony include triethylene glycol ester, glycerol ester, and pentaerythritol ester of hydrogenated colophony.

[0033] Lauric acid is a basic carboxylic acid having 12 C-atoms. It increases the penetration of estradiol through the skin. The proportion of lauric acid contained in the pressure-sensitive adhesive amounts to 1-20% wt., preferably 2-15% wt.

[0034] The reservoir of the recrystallization-free, estrogen agonist-antagonist-containing patch with sufficient active substance release comprises estradiol and its pharmaceutically acceptable derivatives alone or in combination with gestagens at a total concentration of 1 varies as 15% wt., relative to all of the reservoir components, namely in a molar ratio of 1:1 to 1:10.

[0035] The estrogen agonist-antagonist-containing reservoir may comprise at least one component of the group including anti-ageing agents, plasticizers, antioxidants, and absorption improvers. Suitable plasticizers are known to those skilled in the art and are described, for example, in DE 37 43 946. Usually, the proportion of plasticizers in the estrogen agonist-antagonist-containing reservoir amounts to up to 5%-wt.

[0036] In addition, the active substance-containing reservoir also comprises anti-ageing agents in a concentration of up to 1 % wt. These are known to the skilled artisan and are described, for example, in DE 37 43 946.

[0037] The materials for the impermeable backing layer and the removable protective layer are also known to the skilled artisan (e.g., DE 38 43 239).

[0038] The estrogen agonist-antagonist-containing reservoir may either be produced from solution or from the melt.

[0039] Moreover, the reservoir may consist of several layers.

[0040] In case the reservoir has an insufficient self-tackiness to the skin, it may be provided with an additional pressure-sensitive adhesive layer which pressure-sensitive adhesive edge. This ensures that the transdermal patch adheres to the skin over the whole application period.

[0041] A particularly preferred structure of the transdermal estrogen agonist-containing patch is a matrix system wherein, as is generally known, the matrix controls the active substance release and complies with the square root-law according to Higuchi. However, it is understood that a membrane system may well be of advantage in particular cases. In this case, a membrane controlling the active substance release is located between the reservoir and the pressure-sensitive adhesive layer.

[0042] The thickness of the transdermal patch depends on the therapeutic requirements and may be adapted accordingly. Usually, it ranges from 0.03-0.6 mm.

[0043] The transdermal patches of this invention are applied directly to the skin of the patient. Preferred application sites are clean, dry and intact areas of skin, below the waistline on the trunk of the body. Preferably the buttock, hip or abdomen area is chosen since these areas of skin wrinkle least during body movement.

[0044] In the following examples, specific embodiments of the present invention are set forth. These are meant to be illustrative of the invention and are not meant to limit it in any way. All parts and percentages are by weight, unless indicated otherwise.

Example 1


[0045] A seven day patch is prepared by dissolving (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol in a polymer matrix to form a patch which delivers about 10-500 µg per day for seven days.

Example 2


[0046] A fourteen day transdermal patch is prepared by dissolving (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol in a polymer matrix to form a patch which delivers about 10-500 µg per day for fourteen days.

Claims

1. A method of treating a human in need of estrogen agonist-antagonist therapy comprising administering an effective amount of said estrogen agonist-antagonist by transdermal means.
2. The method of claim 1 wherein said transdermal means is a transdermal patch.
3. A method of claim 1 wherein said estrogen agonist-antagonist is selected from a compound of the formula



wherein G is



and
R is H, OH, F or Cl.

4. A method of claim 3 wherein said transdermal patch or a hydrogel composition.
5. A method of claim 3 wherein said transdermal patch is a drug reservoir patch.
6. A transdermal patch which provides administration of said estrogen agonist-antagonist to said human over a period of three to fourteen days in substantially equal amounts of 10-500 µg per day.
7. A transdermal patch comprising a matrix or reservoir and a pharmaceutically effective amount of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt.

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 057 480 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
09.01.2002 Bulletin 2002/02

(51) Int Cl.7: **A61K 9/70**, A61K 31/40,
A61P 5/32, A61K 31/439,
A61K 31/445

(43) Date of publication A2:
06.12.2000 Bulletin 2000/49

(21) Application number: **00304611.7**

(22) Date of filing: **30.05.2000**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(72) Inventor: **Da Silva-Jardine, Paul Andrew**
Groton, Connecticut 06340 (US)

(74) Representative:
Simpson, Alison Elizabeth Fraser et al
Urquhart-Dykes & Lord, 30 Welbeck Street
London W1G 8ER (GB)

(30) Priority: **01.06.1999 US 137164 P**

(71) Applicant: **Pfizer Products Inc.**
Groton, Connecticut 06340 (US)

(54) **Transdermal estrogen agonist-antagonist therapy**

(57) This invention provides a method for transder-
mal delivery of estrogen agonists - antagonists which

are effective for treating or preventing conditions related
to estrogen imbalance.

EP 1 057 480 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 00 30 4611

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	US 5 904 930 A (KLOKKERS KARIN ET AL) 18 May 1999 (1999-05-18) * claim 14; examples *	1,2,4-6	A61K9/70 A61K31/40 A61P5/32 A61K31/439 A61K31/445
X	US 5 605 700 A (KURKELA KAUKO O A ET AL) 25 February 1997 (1997-02-25) * claims *	1,2,4-6	
X	EP 0 843 999 A (PFIZER) 27 May 1998 (1998-05-27) * page 5, line 32,33,51,52 *	1,3,7	
X	EP 0 842 661 A (PFIZER) 20 May 1998 (1998-05-20) * page 9, line 35,36,54,55 *	1,3,7	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>Although claims 1-5 are directed to a method of treatment of the human body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.</p>			
Place of search		Date of completion of the search	Examiner
MUNICH		7 November 2001	Zimmer, B
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone</p> <p>Y : particularly relevant if combined with another document of the same category</p> <p>A : technological background</p> <p>O : non-written disclosure</p> <p>P : intermediate document</p>		<p>T : theory or principle underlying the invention</p> <p>E : earlier patent document, but published on, or after the filing date</p> <p>D : document cited in the application</p> <p>L : document cited for other reasons</p> <p>& : member of the same patent family, corresponding document</p>	

EPO FORM 1503 (03.02.92) (P04027)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 30 4611

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

07-11-2001

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 5904930	A	18-05-1999	DE	4407742 C1	22-06-1995
			AT	203667 T	15-08-2001
			AU	694184 B2	16-07-1998
			AU	1810695 A	25-09-1995
			CA	2185016 A1	14-09-1995
			DE	59509470 D1	06-09-2001
			WO	9524187 A1	14-09-1995
			EP	0748218 A1	18-12-1996
			FI	963515 A	06-09-1996
			JP	9509948 T	07-10-1997
			NO	963749 A	01-11-1996
			PL	316177 A1	23-12-1996
			ZA	9501880 A	11-12-1995
US 5605700	A	25-02-1997	AU	674307 B2	19-12-1996
			AU	3754493 A	08-11-1993
			DE	69323549 D1	25-03-1999
			DE	69323549 T2	29-07-1999
			DK	633774 T3	20-09-1999
			EP	0633774 A1	18-01-1995
			FI	944597 A	03-10-1994
			GR	3029819 T3	30-06-1999
			JP	7505375 T	15-06-1995
			NO	943669 A	30-09-1994
			RU	2140785 C1	10-11-1999
			AT	176757 T	15-03-1999
			CA	2133429 A1	14-10-1993
			EE	2972 B1	15-04-1996
			ES	2129515 T3	16-06-1999
			WO	9319746 A1	14-10-1993
			HU	70845 A2	28-11-1995
			IL	104986 A	14-08-1997
			NZ	249889 A	27-02-1996
			NZ	280219 A	26-05-1997
			ZA	9301760 A	30-09-1993
EP 0843999	A	27-05-1998	AU	735617 B2	12-07-2001
			AU	4518597 A	21-05-1998
			EP	0843999 A1	27-05-1998
			HU	9702039 A2	28-06-1999
			JP	10147522 A	02-06-1998
			US	6124346 A	26-09-2000
			US	6069175 A	30-05-2000
EP 0842661	A	20-05-1998	ZA	9710295 A	14-05-1999
			AT	202702 T	15-07-2001

EPO FORM P0135

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 30 4611

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

07-11-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0842661 A	AU	4523797 A	21-05-1998
	DE	69705480 D1	09-08-2001
	DE	69705480 T2	31-10-2001
	DK	842661 T3	24-09-2001
	EP	0842661 A2	20-05-1998
	ES	2158452 T3	01-09-2001
	HU	9702040 A1	28-11-2000
	JP	10147527 A	02-06-1998
	US	6034102 A	07-03-2000
	ZA	9710292 A	17-05-1999

EPO FCTV 70459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82